Zimmer, ISTO start Phase III study of DeNovo tissue graft

Partners Zimmer Holdings ($ZMH) and orthobiologics company ISTO Technologies are working together on a Phase III clinical study to evaluate the DeNovo ET engineered tissue graft to help repair cartilage defects in the knee. The study will include 225 patients at up to 25 U.S. centers. The program is designed to demonstrate superiority of the graft over the current standard of care for articular cartilage defects. Release

Suggested Articles

Boehringer Ingelheim tapped Healx to help identify new drug indications and leverage its AI to explore R&D options in neurological diseases.

CMR Surgical will have a new CEO at the top of the year, as it kicks off the global launch of its modular Versius system while awaiting FDA approval.

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.